The potential importance of the non^enzymatic glycation of low density lipoproteins (LDL) in atherogenesis and in the accelerated atherosclerosis associated with diabetes is well recognized. However, it has been difficult to evaluate LDL glycation in the clinical setting because of the lack of suitable methods. To approach this problem, we produced monoclonal antibodies, designated ES 12, that recognize glycated apolipoprotein B epitopes in the LDL complex in human plasma. Here we report the use of these antibodies in a competitive enzyme-linked imniunosorbent assay (ELISA) to measure glycated LDL concentrations in plasma from non-diabetic and diabetic subjects. In this assay, glycated LDL in the soluble phase inhibits binding of the ES 12 antibody to glycated LDL immobilized to microtitre wells, whereas other glycated proteins and non-glycated LDL do not compete. A linear dose-response relationship for 10 -125 ng glycated LDL per well allows the construction of standard curves, from which the concentration of glycated LDL in human plasma can be determined. The mean concentration of glycated LDL in samples from non-diabetic subjects was 21.8 + 0.9 mg/1, increasing to 40.8 ± 2.6 mg/1 in samples from patients with type II diabetes, comprising 1.9-4.8% and 3.2-14.8%, respectively, of total apolipoprotein B. Glycated LDL concentrations in samples from diabetic patients correlated positively and significantly with other indices of glycaemic status. The results indicate that circulating glycated LDL, which may have diagnostic and pathophysiologic importance, is increased in diabetes with attendant hyperglycaemia. The results further indicate that the described monoclonal antibody^based competitive ELISA affords a simple and reproducible method for quantitative measurement of glycated LDL.
Introduction
··.,,. ι · ι -siderable interest, because it has been implicated in Non-enzymatic glycation is a condensation reaction the premature and severe atherosclerosis associated between glucose and reactive protein amino groups with diabetes mellitus, and LDL glycation is one of at the NH 2 -terminus or e-amino groups of lysine the post-secretory modifications believed to affect its residues. In diabetic subjects, hyperglycaemia pro-atherogenic potential. For example, internalization motes increased non-enzymatic glycation of circulat-and degradation by cultured fibroblasts of LDL from ing and tissue proteins, thereby allowing assessment patients with insulin-dependent diabetes and poor of integrated glycaemic control through determina-metabolic control is decreased, compared with that tion of glycohaemoglobin and glyco lbumin concen-of LDL isolated from normal subjects or from patrations, and also providing insight into pathogenetic tients with insulin-dependent diabetes and good metmechanisms associated with chronic complications of abolic control (1) . Glycation of LDL diminishes the diabetes. The non-enzymatic glycation of apolipopro-high affinity LDL receptor-mediated uptake and deteinB, the principal protein of the cholesterol-carrying gradation of LDL (2-7), and may promote interlow density lipoproteins (LDL), has generated con-nalization by alternative receptors of monocyte-mac-rophages that give rise to foam cells (8) (9) (10) (11) (12) . Additionally, glycation alters the rate of clearance of LDL in vivo, and may interfere with intracellular handling of cholesterol and regulation of its synthesis (4, 13, 16) . Further, non-enzymatically glycated proteins may have accelerated rates of free radical production (17, 18) , which could increase lipid peroxidation and thereby enhance LDL atherogenicity through formation of modified apolipoprotein B adducts that are recognized and internalized by the classic macrophage scavenger receptor (19) (20) (21) . Some (22, 23) but not all (24) investigators propose that glucose auto-oxidation and sequential modification by glycation and oxidation ("glycoxidation") contribute to increased atherogenesis in diabetes.
Although the potential importance of elevated glycated LDL concentrations in atherogenesis is well recognized, suitable methods for quantitative analysis of plasma glycated LDL have been lacking. To approach this problem, we established hybridomas secreting monoclonal antibodies that recognize glycated epitopes residing in the apolipoprotein B of the LDL complex but not in other plasma proteins (25) . These antibodies, which have been designated ES 12, react on Western blotting and in immunoassay with polypeptides in the LDL complex in human plasma; the polypeptides show co-identity with apolipoprotein B on separate immunoblotting when reacted with apolipoprotein B-specific monoclonal antibodies. In the present study, we report measurement of glycated LDL in human plasma with a competitive enzymelinked immunosorbent assay (ELISA) that employs the ES12 monoclonal antibodies. Results are expressed as μg (glycated) apolipoprotein B equivalents, and can be converted to the fraction (percent) of apolipoprotein B that is glycated by dividing by the total apolipoprotein B concentration, measured independently, in a sample. With this assay, the concentration of glycated LDL in plasma obtained from patients with type II diabetes was approximately one and a half fold greater than that found in samples from non-diabetic individuals, and correlated with other indices of integrated glycaemic status.
Materials and Methods

Preparation of glycated proteins
Glycated LDL was isolated from human LDL (Sigma Chem Co.) by chromatography on a column of phenylboronate agarose, which binds cw-diol groups of sugars. Some LDL preparations were chromatographed without pretreatment, while others were first subjected to glycation in vitro. LDL preparations were first examined for contaminating immunoglobulins which, if present, were removed by immunoadsorption with anti-human immunoglobulin polyclonal antibody. After equilibration and washing, the glycated protein was eluted from the phenylboronate agarose column with 100 mmoi/1 sofbitol (26) . The amount of glycated LDL in the eluant was determined as apolipoprotein B equivalents, measured as micrograms apolipoprotein B by competitive immunoassay using a murine monoclonal antibody B36 (see below) which had been raised against purified human apolipoprotein B-10p (Scripps Laboratories, San Diego, CA). In vitro glycation was performed by incubating LDL for five days at room temperature under a nitrogen atmosphere in 0.15 mol/1 saline/1 mmol/1 EDTA, pH 7.4, containing 5 g/1 glucose, followed by dialysis against saline/EDTA to remove unbound glucose. Unretained material from the loading of the phenylboronate agarose column was used as a source of non-glycated protein.
Glycated albumin was purified from human plasma by sequential chromatography on Affirgel blue and phenylboronate agarose as described (27) . Glycated haemoglobin was purified from lysates of human erythrocytes by sequential ion exchange (BioRex 70) and affinity (phenylboronate agarose) chromatography (26) .
Generation of monoclonal antibodies
The production and partial characterization of the ES 12 monoclonal antibodies to glycated LDL has been described (25) . In brief, male BALB/c mice were immunized by intraperitoneal injection of glycated apolipoprotein B, which was prepared by incubation of purified apolipoprotein B with 5 g/1 glucose in saline/EDTA for three days, followed by dialysis and affinity chromatography on phenylboronate agarose. Spleen cells from immunized animals were fused with SP 2/0 myeloma cells and hybridoma colonies were established according to standard techniques (28) . The resulting colonies, which displayed preferential binding activity to glycated apolipoprotein B and to glycated LDL in direct ELISA, were cloned at least three times by limiting dilution. The colony designated ESI2 secreted antibodies discriminating between glycated versus non-glycated apolipoprotein B and exhibiting the same discrimination for glycated versus non-glycated LDL. On immunoblotting and in direct ELISA these antibodies reacted with glycated epitopes residing within the apolipoprotein B of the LDL complex, did not react with non-glycated LDL, and did not react with other circulating proteins, whether glycated or not (25) . Metal-catalysed oxidation of glycated LDL abolished reactivity with the antibodies, indicating that the recognized epitope is glucosemodified and not a lipid oxidation or glycoxidation product (25) . The ES 12 antibodies, shown by Ouchterlony diffusion to be of the IgGi class, were purified from culture supernatant or from mouse ascites fluid by protein G affinity chromatography, and used for development of a competitive ELISA for measuring glycated LDL in human plasma.
Antibodies to the apolipoprotein B were generated in male BALB/c mice following the schedule described above, using apolipoprotein B-100 (Scripps Laboratories) as immunogen. The colony designated B36 secreted antibodies recognizing purified apolipoprotein B-100 (Scripps) and apolipoprotein B in LDL (Sigma Chem Co) and unreactive with apolipoprotein Α-Ι or high density lipoprotein (Sigma) (25) . The B36 antibodies do not discriminate between glycated versus non-glycated apolipoprotein B. The B36 antibodies, which are of the IgGi class, were purified from mouse ascites fluid by protein G affinity chromatography and used for development of the competitive ELISA for measuring apolipoprotein B.
Competitive ELISA for glycated LDL .Plastic microtitre wells (Nunc Polysorb) were coated with antigen (250 ng protein per well) by iqcubation for 18 hours at room temperature in carbonate-bicarbonate coupling buffer, pH 8.5. After washing to remove unbound material, wells were blocked with 0.1 mol/1 Tris HC1, pH 7.5, containing fetal bovine serum, volume fraction 0.1, and stored at 4°C in the same buffer until use. The wash buffer contained 0.05 mol/1 triethylamine, 0. 
Results
The ES 12 monoclonal antibodies used in these experiments recognize epitopes contained within high molecular mass polypeptides of purified glycated LDL; identical bands were visualized when human plasma was transferred to nitrocellulose after SDS gel electrophoresis and immunoblotted with the ES 12 antibody (25) . These polypeptide bands have been shown to have co^-identity with apolipoprotein B by separate immunoblotting with the B36 monoclonal antibody, which was raised against apolipoprotein B-100 and does not discriminate between glycated versus nonglycated apolipoprotein B (25).
Glycated LDL added in the soluble phase with the ESI2 monoclonal antibody competitively inhibited binding of the antibody to glycated LDL immobilized onto the microtitre wells. The phenylboronate agarose-adsorbed fraction of unincubated LDL or glucose-incubated LDL contained glycated LDL that immunoreacted in competitive ELISA with the ES 12 antibody, whereas unretained material from the phenylboronate agarose did not react ( fig. 1 ). LDL glycated in vitro exhibited immunoreactivity identical to "in vivo" glycated LDL on Western blotting (not fig. 2 ). Mean intra-assay and inter-assay coefficients of variation were 7% and 10%, respectively, in 4 measurements in each of 4 samples.
The samples from diabetic subjects were obtained from patients with type II diabetes whose therapeutic regimens had not changed during the three months before the samples were drawn. Eight were receiving a single injection of intermedi fe-acting insulin, ten were receiving an oral hypoglycaemic agent, and none was performing home-glucose monitoring. Concentrations of glycohaemoglobin and glycoalbumin in samples obtained on the same day as those used for glycated LDL analysis ranged from 7.7 to 15.0% and 1.1 to 3.7%, respectively, indicating varying degrees of integrated glycaemic control, as would be anticipated in patients on unchanging therapeutic programmes. In these patients, the correlation (r) value between glycohaemoglobin and glycoalbumin was 0.86, indicating that integrated glycaemia during the two weeks before sampling approximated that during the 2-3 months before sampling; in other words, patients with elevated glycohaemoglobin also had increased glycoalbumin concentrations, reflecting chronic and unchanged hyperglycaemia during the preceding 2 -10 weeks, whereas patients with normal glycohaemoglobin also had normal glycoalbumin concentrations, reflecting stability of glycaemic control during the preceding 2-10 weeks. Therefore, correlation of glycated LDL concentrations with these other indicators of integrated glycaemic control was sought, on the assumption that ambient glycaemia during the week before sampling (estimated circulating half-life of LDL is 3 -5 days (29) ) in these subjects probably approximated that during the preceding 2-10 weeks. Figure 3 illustrates these correlations with r values of 0.67 between glycohaemoglobin and glycated LDL concentrations, and 0.77 between glycoalbumin and glycated LDL concentrations.
Discussion
In developing an immunoassay for glycated LDL, we considered it important that the antibodies used in the assay discriminate between glycated versus nonglycated or oxidatively modified LDL, that they react with Amadori products of the glycated protein, and that they distinguish glycated LDL from other circulating glycated proteins. The desirability of antibodies with these characteristics is clear, since the much greater plasma concentration of non-glycated LDL or other glycated protein (e. g. albumin) would obfuscate results if the antibodies lacked adequate discrimination. Similarly, cross-reactivity with lipid oxidation products might confuse the assay results. Further, the Amadori rearrangement of the condensation reaction between glucose and reactive protein amino groups is the predominant form in which nonenzymatically glycated proteins exist in vivo. The ES 12 monoclonal antibody satisfies these requirements, given that it does not react with non-glycated apolipoprotein B/LDL or with other circulating proteins, whether glycated or not, recognizes glycated LDL formed in vivo, consistent with the Amadori product, and does not recognize oxidatively or glycoxidatively modified LDL (25) .
Apolipoprotein B is the principal protein of LDL, the major carrier of plasma cholesterol. Apolipoprotein B is a complex macromolecule that exists in two primary forms in human plasma (30, 31) , and it is the protein determinant for the cellular recognition and uptake of LDL by the LDL receptor (32) (33) (34) (35) . The binding of apolipoprotein B to the LDL receptor results in internalization and degradation of LDL, promoting the clearance of LDL from the plasma and regulating intracellular cholesterol handling and biosynthesis (36) (37) (38) . Glycatipn of lysine residues in apolipoprotein B may compromise receptor-mediated internalization and catabolism of LDL, thereby interfering with cholesterol homeostasis and contributing to the pathogenesis of atherosclerosis (1, 4-8, 13,16, 39) . Thus, direct assessment of LDL glycation may have diagnostic and epidemiologic importance as a bio-marker for atherogenic risk, especially in diabetic populations. Additionally, the 3 -5 day circulating half-life of LDL (29) suggests that measurement of glycated LDL could provide an objective index of integrated short-term glycaemic control in diabetic subjects, although there are reports that glycation can prolong or accelerate LDL clearance (2, 13, 15, 40, 41) .
The results presented in this study demonstrate that plasma glycated LDL concentrations can be specifically measured by enzyme-linked immunosorbent assay using a unique and highly specific monoclonal antibody that recognizes glycated apolipoprotein B epitopes in the LDL complex (25) . The assay shows a linear dose response at concentrations between 0.2 and 2.5 mg/1 (10 to 125 ng per 50 μΐ aliquot), encompassing the range found in a 50 μΐ aliquot of plasma diluted 1 :20 for assay (20-60 mg/1; 50-150 ng in 50 μΐ of 1 : 20 dilution). Plasma glycated LDL concentrations in diabetic subjects were found to be significantly greater than in non-diabetic subjects and, in patients in whom therapy had remained unchanged for 2 -3 months before sampling, showed positive and significant correlation with glycohaemoglobin and glycoalbumin concentrations. The amount of glycated LDL determined with this assay, expressed as percent of total apolipoprotein Β that is glycated, is consistent with that estimated in previous studies using phenylboronate agarose affinity chromatography to separate glycated LDL (42) (43) (44) .
Previously, measurement of the amount of glycated LDL has required isolation of the LDL complex followed by separation of glycated from non-glycated species with affinity chromatography on phenylboronate, then determination of the amount of LDL in the different fractions by gel electrophoresis with densitometric scanning or by immunochemical analysis. The competitive ELISA described herein does not require extraction, chromatography, or sample pretreatment (other than dilution), and can easily be completed within two hours. Results are quantitative and reproducible and confirm that non-enzymatic glycation of LDL, like that of other circulating proteins, is increased in diabetes with attendant hyperglycaemia. The availability of this assay should allow epidemiologic studies and correlative analyses in diabetic populations for assessing the predictive value and risk for atherosclerotic disease associated with elevated levels of glycated LDL. Measurement of glycated LDL could also provide an index of shortterm integrated glycaemia that may prove clinically useful in the management of diabetes.
